Thomas Klitgaard

Summary

Affiliation: Novo Nordisk A/S
Country: Denmark

Publications

  1. ncbi Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Building 9ES 20, Krogshøjvej 53A, 2880 Bagsvaerd, Denmark
    Growth Horm IGF Res 19:463-70. 2009
  2. ncbi Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Maaloev, Denmark
    Crit Care 10:R104. 2006
  3. ncbi Overview of the human pharmacokinetics of recombinant activated factor VII
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Bagsvaerd, Denmark
    Br J Clin Pharmacol 65:3-11. 2008
  4. ncbi Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile
    Michael Højby Rasmussen
    Departments of Medical and Science, Novo Nordisk A S, DK 2880 Bagsvaerd, Denmark
    J Clin Endocrinol Metab 95:3411-7. 2010
  5. ncbi Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial
    Irene H Langbakke
    Department of Clinical Pharmacology, Novo Nordisk A S, Bagsvaerd, Denmark
    Clin Endocrinol (Oxf) 67:776-83. 2007
  6. ncbi Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma
    Birgitte Scharling
    Novo Nordisk A S, Bagsvaerd, Denmark
    Blood Coagul Fibrinolysis 18:677-84. 2007
  7. ncbi Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile
    Michael Højby Rasmussen
    Global Development, Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Clin Endocrinol (Oxf) 73:769-76. 2010

Collaborators

Detail Information

Publications7

  1. ncbi Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Building 9ES 20, Krogshøjvej 53A, 2880 Bagsvaerd, Denmark
    Growth Horm IGF Res 19:463-70. 2009
    ..To develop a population pharmacokinetic (PK) model of recombinant human growth hormone (rhGH) treatment in patients with end-stage renal disease (ESRD) and healthy volunteers (HVs), to support future study design...
  2. ncbi Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Maaloev, Denmark
    Crit Care 10:R104. 2006
    ..Recombinant activated factor VII (rFVIIa) has been used as adjunctive therapy in trauma patients with severe bleeding. However, its pharmacokinetics profile remains unknown...
  3. ncbi Overview of the human pharmacokinetics of recombinant activated factor VII
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Bagsvaerd, Denmark
    Br J Clin Pharmacol 65:3-11. 2008
    ..To review the pharmacokinetics of rFVIIa in various patient populations, and to discuss the differences observed between groups...
  4. ncbi Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile
    Michael Højby Rasmussen
    Departments of Medical and Science, Novo Nordisk A S, DK 2880 Bagsvaerd, Denmark
    J Clin Endocrinol Metab 95:3411-7. 2010
    ..NNC126-0083 is a pegylated rhGH developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration...
  5. ncbi Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial
    Irene H Langbakke
    Department of Clinical Pharmacology, Novo Nordisk A S, Bagsvaerd, Denmark
    Clin Endocrinol (Oxf) 67:776-83. 2007
    ..GH may be beneficial in treating patients with end-stage renal disease (ESRD). However, the efficacy and safety of GH could be compromised by the potential for accumulation in the circulation...
  6. ncbi Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma
    Birgitte Scharling
    Novo Nordisk A S, Bagsvaerd, Denmark
    Blood Coagul Fibrinolysis 18:677-84. 2007
    ....
  7. ncbi Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile
    Michael Højby Rasmussen
    Global Development, Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Clin Endocrinol (Oxf) 73:769-76. 2010
    ..The current study examined safety, tolerability, pharmacokinetic and pharmacodynamic response parameters after single and multiple doses of a long-acting rhGH preparation (NNC126-0083)...